Therapy Areas: Autoimmune
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
28 January 2026 - Biotechnology company Biogen Inc (Nasdaq:BIIB) announced on Wednesday that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BII...
HanchorBio partners with WuXi Biologics for development and manufacturing of next-gen bi- and multi-functional fusion programmes
27 January 2026 - HanchorBio Inc (TPEx:7827), a clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, announced on Monday that it has ent...
Roivant to announce Q3 2026 financial results
26 January 2026 - Biopharmaceutical company Roivant (Nasdaq:ROIV) said on Friday that it will host a live conference call and webcast on Friday, 6 February 2026, to report its financial results for th...
AbbVie licenses PD-1/VEGF bispecific antibody RC148 from RemeGen in multi-billion dollar oncology deal
12 January 2026 - Oncology company AbbVie (NYSE: ABBV) and biopharmaceutical company RemeGen announced on Monday that the companies have entered into an exclusive licensing agreement for the developme...
HUTCHMED reports positive Phase III results for sovleplenib in wAIHA
7 January 2026 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq/AIM: HCM) (HKEX: 13) on Wednesday reported positive topline results from the Phase III registration part of the ESLIM-02 tri...
Physiomics secures follow-on UK contract for Phase 2 study support
15 December 2025 - Physiomics plc (AIM: PYC), a mathematical modelling, data science and biostatistics company, announced on Monday that it has been awarded a follow-on contract with an existing UK cl...